Recent developments in the legal battle over the planned $3.3 billion UnitedHealth Group (NYSE: UHG) acquisition of Amedisys (Nasdaq: AMED) have moved the ...
Zacks.com on MSN3d
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?The market expects Amedisys (AMED) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback